In a significant move aimed at revolutionizing Central Nervous System (CNS) research, eCOA/ePRO platform provider uMotif has announced a strategic partnership with MoCA Cognition, the creators of a recognized test for early cognitive impairment detection.
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
A partnership between clinical research technology company uMotif and cognitive science company, Cogstate Limited, will see the companies continue existing work that includes a major phase 2 clinical trial of a psychedelic therapeutic.
uMotif is starting to reap the rewards of its patient first technology – that really does what it says on the tin, says the company’s CEO, Steve Rosenberg.